Table 3.
Clinical characteristics of DC Cohort and non-DC cohort participants living in DC as of December 2017 (n=12,964).
| Characteristic | DCa cohort | Non-DC cohortb | P value | |
| Ever stage 3 diagnosis (eg, AIDS, CD4 <200 cells/µL, or OIc), n (%) | 3093 (59.6) | 3652 (47.0) | <.001 | |
| Engaged in HIV care in 2017, n (%) | 4336 (83.5) | 5572 (71.7) | <.001 | |
| CD4 count (cells/µL) in 2017, median (IQRd) | 618 (440) | 610 (431) | .83 | |
| CD4 count (cells/µL), most recent |
|
|
.19 | |
|
|
<200, n (%) | 365 (8.5) | 455 (8.4) | — |
|
|
200-500, n (%) | 1159 (27.0) | 1495 (27.6) | — |
|
|
>500, n (%) | 2764 (64.5) | 3473 (64.0) | — |
| Virally suppressede between 2011-2017, n (%) | 4348 (83.7) | 6070 (78.1) | <.001 | |
| Virally suppressede at last lab in 2017, n (%) | 3189 (61.4) | 3921 (50.5) | <.001 | |
| Time to first known viral suppressione, n (%) |
|
|
<.001 | |
|
|
0-24 months | 1472 (33.4) | 2382 (39.2) | — |
|
|
>24 months | 2876 (65.6) | 3688 (60.7) | — |
aDC: District of Columbia.
bNon-DC Cohort participants include persons who have consented and subsequently withdrawn from the study, as well as persons diagnosed with HIV and reported to the DC Health who were alive as of the end of December 2017.
cOI: opportunistic infection.
dIQR: interquartile range.
eViral suppression defined as HIV RNA <200 copies/mL.